Cardiff Oncology, Inc.CRDFNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-29.21%
↓ 565% below average
Average (39q)
6.29%
Historical baseline
Range
High:56.08%
Low:-77.06%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -29.21% |
| Q2 2025 | 10.53% |
| Q1 2025 | 7.88% |
| Q4 2024 | 0.75% |
| Q3 2024 | 1.55% |
| Q2 2024 | 18.54% |
| Q1 2024 | 3.16% |
| Q4 2023 | -3.23% |
| Q3 2023 | 0.02% |
| Q2 2023 | -11.40% |
| Q1 2023 | 40.52% |
| Q4 2022 | 7.21% |
| Q3 2022 | -19.32% |
| Q2 2022 | 3.33% |
| Q1 2022 | 23.76% |
| Q4 2021 | 40.20% |
| Q3 2021 | 0.85% |
| Q2 2021 | 25.62% |
| Q1 2021 | 2.50% |
| Q4 2020 | 12.06% |
| Q3 2020 | 15.31% |
| Q2 2020 | -8.50% |
| Q1 2020 | -5.53% |
| Q4 2019 | 1.62% |
| Q3 2019 | -0.39% |
| Q2 2019 | 6.83% |
| Q1 2019 | 6.09% |
| Q4 2018 | 36.42% |
| Q3 2018 | -6.26% |
| Q2 2018 | 3.66% |
| Q1 2018 | 56.08% |
| Q4 2017 | -14.68% |
| Q3 2017 | 44.11% |
| Q2 2017 | -77.06% |
| Q1 2017 | 13.07% |
| Q4 2016 | -3.87% |
| Q3 2016 | -3.41% |
| Q2 2016 | 27.07% |
| Q1 2016 | 1.33% |
| Q4 2015 | 24.33% |